Abstract
Testicular cancer is a rare cancer that often affects young and otherwise healthy
patients. Imaging plays a critical role in the staging and surveillance of patients
with testicular cancer. Indeterminate findings on staging or surveillance imaging,
can lead to challenging management decisions for clinicians and patients. In this
article, we review the importance of short-interval, repeat imaging for several scenarios
faced by patients with testicular cancer and their clinicians. The challenging scenarios
and recommendations provided in this article summarize the discussion from the inaugural
Global Society of Rare Genitourinary Tumors (GSRGT) Summit held on December 11-12,
2020.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
World Health Organization. Testis - Source: Globocan 2020. Published online 2020:9-10.
- Annual report to the nation on the status of cancer, part I: National cancer statistics.Cancer. 2020; 126: 2225-2249https://doi.org/10.1002/cncr.32802
- Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.Lancet Oncol. 2007; (Published online)https://doi.org/10.1016/S1470-2045(07)70246-2
- Testicular cancer survivorship.JNCCN. 2019; 17: 1557-1568https://doi.org/10.6004/jnccn.2019.7369
- Testicular cancer: determinants of cisplatin sensitivity and novel therapeutic opportunities.Cancer Treatment Rev. 2020; (Published online)https://doi.org/10.1016/j.ctrv.2020.102054
- Non–risk-adapted surveillance for stage I testicular cancer: critical review and summary [Figure presented].Eur Urol. 2018; 73: 899-907https://doi.org/10.1016/j.eururo.2017.12.030
- Active surveillance in stage 1 disease: standard of care independent of risk factors?.Curr Opin Urol. 2020; (Published online)https://doi.org/10.1097/MOU.0000000000000708
- Diagnosis and treatment of early stage testicular cancer: AUA guideline.J Urol. 2019; 202: 272-281https://doi.org/10.1097/JU.0000000000000318
- Testicular cancer, version 2.2020.JNCCN J Natl Compr Cancer Netw. 2019; 17: 1529-1554https://doi.org/10.6004/jnccn.2019.0058
Nauman M, Leslie SW. Nonseminomatous testicular tumors; 2021.
- Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.J Can Urol Assoc. 2018; 12: 59-66https://doi.org/10.5489/cuaj.4531
- Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.J Natl Comprehens Cancer Netw. 2019; (Published online)https://doi.org/10.6004/jnccn.2019.0058
- Reliability of serum tumor marker measurement to diagnose recurrence in patients with clinical stage I nonseminomatous germ cell tumors undergoing active surveillance: a systematic review.J Urol. 2021; (Published online)https://doi.org/10.1097/JU.0000000000001685
- Distribution of retroperitoneal lymph node metastases in testicular germinal tumors.Cancer. 1974; 33: 340-348https://doi.org/10.1002/1097-0142(197402)33:2<340::AID-CNCR2820330207>3.0.CO;2-Y
- Testicular cancer: what the radiologist needs to know.Am J Roentgenol. 2013; 200: 1215-1225https://doi.org/10.2214/AJR.12.10319
Hilton S, Teitcher JB, Begg CB, Castehlmno RA. Germ cell cancer: size and distribution. 1997:521-525.
- Lymphadenopathy.Mayo Clin Proc. 2000; 75: 723-732https://doi.org/10.5005/jp/books/12296_70
- Unexplained lymphadenopathy: evaluation and differential diagnosis.Am Fam Phys. 2016; 94: 896-903
- Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor.Am J Roentgenol. 2014; (Published online)https://doi.org/10.2214/AJR.13.11615
- Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.J Clin Oncol. 2009; (Published online)https://doi.org/10.1200/JCO.2008.18.8953
- Edn. Presented at the EAU Annual Congress, Milan2021
- Is surveillance without immediate treatment an option for newly diagnosed testicular germ-cell cancer patients with borderline size retroperitoneal lymph nodes on computed tomography scan?.J Clin Oncol. 2018; 36: 560https://doi.org/10.1016/j.juro.2018.02.1212
- State-of-the-art management of germ cell tumors.Am Soc Clin Oncol Educ Book. 2018; (Published online)https://doi.org/10.1200/edbk_201139
- The PRIMETEST trial: interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.J Clin Oncol. 2019; (Published online)https://doi.org/10.1200/jco.2019.37.7_suppl.507
- SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma.J Clin Oncol. 2021; (Published online)https://doi.org/10.1200/jco.2021.39.6_suppl.375
- Medical treatment of advanced testicular cancer.JAMA. 2008; 299: 672-684
- Teratoma with malignant transformation in germ cell tumors in men.Cancer. 1985; (Published online)https://doi.org/10.1002/1097-0142(19850815)56:4<860::AID-CNCR2820560426>3.0.CO;2-3
- Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: The significance of histology with particular reference to differentiated (mature) teratoma.Br J Cancer. 1984; (Published online)https://doi.org/10.1038/bjc.1984.226
- Mature and immature teratoma: a review of pathological characteristics and treatment options.Med & Surg Urol. 2014; (Published online)https://doi.org/10.4172/2168-9857.1000124
- Long-term surveillance of patients with complete response following chemotherapy for metastatic nonseminomatous germ cell tumor.Eur Urol Oncol. 2021; (Published online)https://doi.org/10.1016/j.euo.2020.08.007
- The management of residual masses after chemotherapy in metastatic seminoma.BJU Int. 1999; (Published online)https://doi.org/10.1046/j.1464-410X.1999.00974.x
- Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.BioMed Res Int. 2014; (Published online)https://doi.org/10.1155/2014/852681
- Complications of post-chemotherapy retroperitoneal lymph node dissection.J Urol. 1995; 153 (Published online): 976-980
- Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection.Eur Urol. 2009; (Published online)https://doi.org/10.1016/j.eururo.2008.09.027
- Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections.Eur J Cancer. 1994; (Published online)https://doi.org/10.1016/0959-8049(94)90164-3
- Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumors.Br J Cancer. 2000; (Published online)https://doi.org/10.1054/bjoc.2000.1416
- Campbell Walsh Urology 11th Edition - Chapter 35 - Surgery of Testicular Tumors.Elsevier, Philedelphia, PA2016
- Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature.World J Surg Oncol. 2020; 18: 253https://doi.org/10.1186/s12957-020-02032-1
- Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor.J Urol. 2018; (Published online)https://doi.org/10.1016/j.juro.2018.02.068
- Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.Eur Radiol. 2020; 30: 2334-2345
- Can whole-body MRI replace CT in management of metastatic testicular cancer? A prospective, non-inferiority study.J Cancer Res Clin Oncol. 2022; (0123456789)https://doi.org/10.1007/s00432-022-03996-1
- Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.Curr Urol Rep. 2018; (Published online)https://doi.org/10.1007/s11934-018-0863-3
Article info
Publication history
Published online: December 21, 2022
Accepted:
December 15,
2022
Received in revised form:
December 13,
2022
Received:
November 21,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Published by Elsevier Inc.
